Market Overview:
The global latanoprost market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as an increase in the prevalence of glaucoma, rising awareness about glaucoma and its treatment, and increasing demand for generic drugs. However, patent expiries of key branded drugs are expected to restrain the growth of the market during the forecast period. Based on type, the global latanoprost market is segmented into brand drug and generic drug. The brand drug segment is further sub-segmented into Xalatan (Pfizer) and Lumigan (Allergan). The generic drug segment is further sub-segmented into latanoprost ophthalmic solution (generic Xalatan) and latanoprost ophthalmic suspension (generic Lumigan). Based on application, the global latanoprost market is divided into open-angle glaucoma and close-angle glaucoma. Geographically, it has been analyzed across North America, Latin America, Europe Asia Pacific & Middle East & Africa regions.
Product Definition:
Latanoprost is a prostaglandin analogue used as eye drops to lower intraocular pressure in people with open-angle glaucoma or ocular hypertension. It is marketed under the trade name Xalatan.
Brand Drug:
A brand drug is a pharmaceutical product with a unique name, which is registered with the U.S. FDA and European Medicines Agency (EMA). The drugs are protected by patents and the company that develops it files for exclusive rights to market it in the U.S. or Europe once the patent expires.
Generic Drug:
A generic drug is a pharmaceutical product that has an active ingredient similar to that of a branded drug but which has been approved by the Food and Drug Administration (FDA) for sale in the U.S. as well as other countries. The FDA does not conduct clinical trials on generic drugs; instead, it relies upon information provided by the manufacturer of the original patented drug and determines whether or not it is substantially equivalent to the innovator's product.
Application Insights:
The open-angle glaucoma segment held the largest share of 41.1% in 2017. The rising prevalence of open-angle glaucoma, which is caused by a rise in the number of people susceptible to its effects due to higher exposure to UV radiation and other factors is expected to be one of the major drivers for this application segment over the forecast period.
The close-angle glaucoma segment is anticipated register a CAGR around 14.0% from 2018 to 2030 owing to increasing awareness about early diagnosis and treatment coupled with availability of advanced products at affordable prices that are suitable for use in both developed as well as developing countries globally.
Regional Analysis:
North America dominated the global market in 2017. The growth is attributed to the rising prevalence of glaucoma and other ophthalmic diseases, such as diabetic retinopathy, in this region. According to data published by National Eye Institute (NIH), around 6 million people are suffering from open-angle glaucoma (OAG) and 2 million people have closed-angle glaucoma (CAG). In addition, a large number of patients are living with undiagnosed cases of these eye diseases which further increases the risk for damage to the optic nerve leading to vision loss. Thus, increasing awareness about early diagnosis is one of the major factors driving regional market growth.
Asia Pacific is expected to witness lucrative CAGD over the forecast period owing high unmet clinical needs coupled with huge population base especially in countries like India & China & Japan etc.
Growth Factors:
- Increasing prevalence of glaucoma and other eye disorders: The increasing prevalence of glaucoma and other eye disorders is one of the key growth drivers for the latanoprost market. According to a study by The Glaucoma Foundation, around 3 million people in the U.S. are affected by glaucoma, and this number is expected to reach 4 million by 2020. This growing population base is likely to drive demand for latanoprost products in the coming years.
- Rising awareness about glaucoma and its treatment options: Another key growth driver for the latanoprost market is rising awareness about glaucoma and its treatment options among patients as well as healthcare professionals across the globe. This growing awareness is likely to boost demand for latanoprost products in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Latanoprost Market Research Report
By Type
Brand Drug, Generic Drug
By Application
Open-angle Glaucoma, Close-angle Glaucoma
By Companies
Pfizer, Mylan, Novartis, Apotex, Teva, Taj Pharma, CR Zizhu
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Latanoprost Market Report Segments:
The global Latanoprost market is segmented on the basis of:
Types
Brand Drug, Generic Drug
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Open-angle Glaucoma, Close-angle Glaucoma
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Mylan
- Novartis
- Apotex
- Teva
- Taj Pharma
- CR Zizhu
Highlights of The Latanoprost Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Brand Drug
- Generic Drug
- By Application:
- Open-angle Glaucoma
- Close-angle Glaucoma
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Latanoprost Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Latanoprost is a medication used to treat glaucoma. It works by reducing the amount of fluid in the eye.
Some of the key players operating in the latanoprost market are Pfizer, Mylan, Novartis, Apotex, Teva, Taj Pharma, CR Zizhu.
The latanoprost market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Latanoprost Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Latanoprost Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Latanoprost Market - Supply Chain
4.5. Global Latanoprost Market Forecast
4.5.1. Latanoprost Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Latanoprost Market Size (000 Units) and Y-o-Y Growth
4.5.3. Latanoprost Market Absolute $ Opportunity
5. Global Latanoprost Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Latanoprost Market Size and Volume Forecast by Type
5.3.1. Brand Drug
5.3.2. Generic Drug
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Latanoprost Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Latanoprost Market Size and Volume Forecast by Application
6.3.1. Open-angle Glaucoma
6.3.2. Close-angle Glaucoma
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Latanoprost Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Latanoprost Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Latanoprost Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Latanoprost Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Latanoprost Demand Share Forecast, 2019-2026
9. North America Latanoprost Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Latanoprost Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Latanoprost Market Size and Volume Forecast by Application
9.4.1. Open-angle Glaucoma
9.4.2. Close-angle Glaucoma
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Latanoprost Market Size and Volume Forecast by Type
9.7.1. Brand Drug
9.7.2. Generic Drug
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Latanoprost Demand Share Forecast, 2019-2026
10. Latin America Latanoprost Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Latanoprost Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Latanoprost Market Size and Volume Forecast by Application
10.4.1. Open-angle Glaucoma
10.4.2. Close-angle Glaucoma
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Latanoprost Market Size and Volume Forecast by Type
10.7.1. Brand Drug
10.7.2. Generic Drug
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Latanoprost Demand Share Forecast, 2019-2026
11. Europe Latanoprost Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Latanoprost Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Latanoprost Market Size and Volume Forecast by Application
11.4.1. Open-angle Glaucoma
11.4.2. Close-angle Glaucoma
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Latanoprost Market Size and Volume Forecast by Type
11.7.1. Brand Drug
11.7.2. Generic Drug
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. ByCountry
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Latanoprost Demand Share, 2019-2026
12. Asia Pacific Latanoprost Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Latanoprost Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Latanoprost Market Size and Volume Forecast by Application
12.4.1. Open-angle Glaucoma
12.4.2. Close-angle Glaucoma
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Latanoprost Market Size and Volume Forecast by Type
12.7.1. Brand Drug
12.7.2. Generic Drug
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Latanoprost Demand Share, 2019-2026
13. Middle East & Africa Latanoprost Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Latanoprost Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Latanoprost Market Size and Volume Forecast by Application
13.4.1. Open-angle Glaucoma
13.4.2. Close-angle Glaucoma
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Latanoprost Market Size and Volume Forecast by Type
13.7.1. Brand Drug
13.7.2. Generic Drug
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Latanoprost Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Latanoprost Market: Market Share Analysis
14.2. Latanoprost Distributors and Customers
14.3. Latanoprost Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Mylan
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Apotex
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Teva
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Taj Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. CR Zizhu
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
